OVID THERAPEUTICS INC
NASDAQ: OVID (Ovid Therapeutics Inc.)
Kemas kini terakhir: 1 jam lalu0.324
0.01 (2.66%)
| Penutupan Terdahulu | 0.315 |
| Buka | 0.324 |
| Jumlah Dagangan | 242,941 |
| Purata Dagangan (3B) | 389,695 |
| Modal Pasaran | 22,999,870 |
| Harga / Jualan (P/S) | 43.85 |
| Harga / Buku (P/B) | 0.360 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2025 - 16 May 2025 |
| Margin Operasi (TTM) | -14,371.05% |
| EPS Cair (TTM) | -0.370 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -46.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 21.63% |
| Nisbah Semasa (MRQ) | 5.32 |
| Aliran Tunai Operasi (OCF TTM) | -55.96 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -29.90 M |
| Pulangan Atas Aset (ROA TTM) | -30.90% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.88% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Ovid Therapeutics Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | 1.50 |
|
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 16.29% |
| % Dimiliki oleh Institusi | 57.13% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 4.00 (BTIG, 1,136.09%) | Beli |
| Median | 3.50 (981.58%) | |
| Rendah | 3.00 (Wedbush, 827.07%) | Beli |
| Purata | 3.50 (981.58%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 0.472 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 24 Mar 2025 | 4.00 (1,136.09%) | Beli | 0.444 |
| Wedbush | 12 Mar 2025 | 3.00 (827.07%) | Beli | 0.500 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Apr 2025 | Pengumuman | Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference |
| 11 Mar 2025 | Pengumuman | Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results |
| 03 Mar 2025 | Pengumuman | Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors |
| 27 Feb 2025 | Pengumuman | Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference |
| 05 Feb 2025 | Pengumuman | Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |